An Adapted Clinical Measurement Tool for the Key Symptoms of CLN2 Disease

AUTOR(ES)

Wyrwich, Kathleen W.

FONTE

J. inborn errors metab. screen.

DATA DE PUBLICAÇÃO

28/02/2019

RESUMO

Abstract Neuronal ceroid lipofuscinosis type-2 (CLN2) disease is a rare, autosomalrecessive,pediatric-onset,neurodegenerative lysosomal storage disease caused by mutations in the TPP1 gene. Cerliponase alfa (Brineura®), a recombinant form of human tripeptidyl peptidase-1, was recently developed as a treatment for CLN2 disease. In clinical trials, the primary end point to evaluate treatment effect was the aggregate score for the motor and language (ML) domains of the CLN2 Clinical Rating Scale, an adaptation of the Hamburg scale’s component items that include anchor point definitions to allow consistent ratings in multinational, multisite, clinical efficacy studies. Psychometric analyses demonstrated that the ML score of the CLN2 Clinical Rating Scale and individual item scores are well defined and possess adequate measurement properties (reliability, validity, and responsiveness) to demonstrate a clinical benefit over time. Additionally, analyses comparing the CLN2 Clinical Rating Scale ML ratings to the Hamburg scale’s ML ratings demonstrated adequate similarity.

Documentos Relacionados

• Physiotherapy for Children with CLN2 Disease
• Nucleotide sequence of the Saccharomyces cerevisiae CLN1 and CLN2 genes.
• Comparison of the Saccharomyces cerevisiae G1 cyclins: Cln3 may be an upstream activator of Cln1, Cln2 and other cyclins.
• Activation of CLN1 and CLN2 G1 cyclin gene expression by BCK2.
• Overexpression of Sis2, Which Contains an Extremely Acidic Region, Increases the Expression of Swi4, Cln1 and Cln2 in Sit4 Mutants